Physician

Charles G Petrunin, M.D.

According to 2025 Medicare claims, Charles Petrunin, M.D. (NPI: 1881788099) practices hematology/oncology in the Salem, OR market, with the plurality of this provider's patient population coming from Marion, OR. This provider's primary affiliated billing organization is OREGON ONCOLOGY SPECIALISTS, LLP (NPI: 1013953025; TIN: 93-1273254) and primary practice location at 97301-3984. Petrunin is affiliated with the CoreHealth Alliance LLC (ACO ID: A5645), participating under the MSSP model.

Petrunin's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 498 traditional Medicare patients, billed 121,916 HCPCS/CPT codes, and received $2,398,661 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,321 prescription claims across 203 beneficiaries totaling $4,793,886 in drug costs, led by Imbruvica (Ibrutinib). 2023 DME data shows 15 claims. Open Payments data shows 10 records totaling $213. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $1,050,566 to $2,398,661. Similarly, Part D prescription costs have risen steadily, from $1,029,518 to $4,793,886. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	458	74,515	$1,050,566
2016	533	101,035	$1,410,322
2017	460	134,719	$1,404,423
2018	524	121,784	$1,636,302
2019	568	133,127	$1,885,501
2020	537	131,664	$2,072,106
2021	520	149,137	$2,599,624
2022	477	126,706	$2,194,495
2023	461	137,323	$2,249,998
2024	498	121,916	$2,398,661

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	191	1,063	$1,029,518
2016	205	1,260	$1,746,133
2017	197	1,372	$1,993,165
2018	179	1,294	$2,987,110
2019	192	1,447	$3,349,246
2020	173	1,384	$2,945,547
2021	168	1,247	$2,893,271
2022	181	1,233	$3,259,415
2023	174	1,225	$2,964,741
2024	203	1,321	$4,793,886

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	25	$20,144
2016	N/R	100	$47,088
2017	N/R	42	$10,930
2018	N/R	85	$13,785
2019	N/R	50	$5,717
2020	N/R	72	$7,043
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	15	$11,263
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	173	436	$96
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	169	241	$65
80053	Blood test, comprehensive group of blood chemicals	381	1,165	$10
36415	Insertion of needle into vein for collection of blood sample	327	905	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	399	1,250	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Imbruvica	Ibrutinib	64	1,792	$1,032,387
Cabometyx	Cabozantinib S-Malate	13	390	$642,993
Ibrance	Palbociclib	37	1,050	$503,985
Lenalidomide	Lenalidomide	52	1,274	$434,914
Pomalyst	Pomalidomide	15	420	$361,430

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	10	$213	Novartis Pharmaceuticals Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Charles G. Petrunin, M.D.?

Tedicare shows public-source Medicare data for Charles G. Petrunin, M.D. (NPI 1881788099), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Charles G. Petrunin, M.D. have ACO affiliation data?

Charles G. Petrunin, M.D. is shown with ACO affiliation data for CoreHealth Alliance LLC (MSSP, ACO ID A5645).

What billing organization is linked to Charles G. Petrunin, M.D.?

Charles G. Petrunin, M.D. is linked to OREGON ONCOLOGY SPECIALISTS, LLP (billing NPI 1013953025) in the available physician profile data.

Does Charles G. Petrunin, M.D. have Open Payments data?

Charles G. Petrunin, M.D. has 10 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.